Loading…
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $19M | $-76M | $-77M | $-43M | -37.0% | 70.9% | 205.2% |
| 2024 | $11M | $-13M | $-25M | $-23M | 41.1% | 11.6% | 293.5% |
| 2023 | $10M | $-6M | $-6M | $56M | 9.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Revenue | 9.76 | 10.90 | 18.62 |
| Operating Revenue | 9.76 | 10.90 | 18.62 |
| Operating Expense | 16.15 | 24.12 | 95.43 |
| Research And Development | 12.65 | 19.20 | 53.76 |
| Selling General And Administration | 3.50 | 4.92 | 41.68 |
| Total Expenses | 16.15 | 24.12 | 95.43 |
| Operating Income | -6.39 | -13.22 | -76.81 |
| Total Operating Income As Reported | -6.39 | -13.22 | -76.81 |
| EBITDA | -6.25 | -13.05 | -76.49 |
| Normalized EBITDA | -6.25 | -13.05 | -76.49 |
| EBIT | -6.39 | -13.22 | -76.81 |
| Other Non Operating Income Expenses | 0 | 0 | -0.01 |
| Other Income Expense | 0 | 0 | -0.01 |
| Pretax Income | -6.38 | -13.22 | -76.83 |
| Tax Provision | 0 | 11.91 | -0.14 |
| Tax Rate For Calcs | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 |
| Net Income Continuous Operations | -6.38 | -25.12 | -76.68 |
| Net Income From Continuing And Discontinued Operation | -6.38 | -25.12 | -76.68 |
| Net Income From Continuing Operation Net Minority Interest | -6.38 | -25.12 | -76.68 |
| Net Income | -6.38 | -25.12 | -76.68 |
| Net Income Common Stockholders | -6.38 | -25.12 | -76.68 |
| Net Income Including Noncontrolling Interests | -6.38 | -25.12 | -76.68 |
| Normalized Income | -6.38 | -25.12 | -76.68 |
| Diluted NI Availto Com Stockholders | -6.38 | -25.12 | -76.68 |
| Basic Average Shares | 17.11 | 17.11 | 17.11 |
| Diluted Average Shares | 17.12 | 17.12 | 17.11 |
| Reconciled Depreciation | 0.14 | 0.17 | 0.32 |
| General And Administrative Expense | 3.50 | 4.92 | 41.68 |
| Other Gand A | 3.50 | 4.92 | 41.68 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Atrium Therapeutics, Inc.this co. | RNA | $210M | -2.74 | 1.02 | -37.0% | 0.73 |
| Utah Medical Products, Inc. | UTMD | $216M | 19.17 | 1.82 | 9.5% | 9.09 |
| Pro-Dex, Inc. | PDEX | $214M | 23.83 | 5.84 | 24.5% | 16.29 |
| Keros Therapeutics, Inc. | KROS | $213M | 2.45 | 0.70 | 28.7% | -0.83 |
| RxSight, Inc. | RXST | $211M | -5.42 |
| 0.77 |
| -14.1% |
| -5.68 |
| Accendra Health, Inc. | ACH | $203M | -0.18 | -0.44 | 238.8% | 9.29 |
| Sanara MedTech Inc. | SMTI | $203M | -5.40 | 34.13 | -632.5% | 22.72 |
| TriSalus Life Sciences, Inc. | TLSI | $203M | -5.17 | -5.99 | 115.8% | -6.56 |
| Embecta Corp. | EMBC | $202M | 2.12 | -0.31 | -14.6% | 4.95 |
| Peer Median | - | 0.97 | 0.73 | 17.0% | 7.02 | |